Applying Genomics to Breast Cancer Care: Lessons from SABCS 2021
Studies presented at SABCS 2021 demonstrated the feasibility and clinical utility of genomic profiling in breast cancer.
Breast Cancer
Researchers Pinpoint Distinct Features of Breast Cancer Subtypes
Overall survival was largely similar across subtypes but was superior in ductal plus lobular carcinoma.
Breast Cancer Survivors Face Higher Risk for Hypertension, Diabetes
The risk of hypertension was even higher for those receiving left-sided radiation or endocrine therapy.
Survival Benefit Persists With Ribociclib in HR+/HER2- Advanced Breast Cancer
Ribociclib prolonged overall survival at a median follow-up of 53.5 months.
Overall Breast Cancer Incidence Decreased From 1999 to 2018
The incidence of breast cancer decreased overall from 1999 to 2018 but increased for non-Hispanic Asian/Pacific Islander women.
Dense Breasts, High BMI May Interact to Up Breast Cancer Risk
Increased breast density was associated with an increased risk for breast cancer in premenopausal and postmenopausal women across BMI categories.
Phase 3 Studies Herald More Options for Metastatic Breast Cancer
Dr Alan Lyss details the results and clinical implications of the EMERALD, PHOEBE, and DESTINY-Breast03 trials.
Incidence of Advanced Lung Cancer Continues to Decline in the U.S.
Researchers projected that 1,918,030 new cancer cases and 609,360 cancer deaths will occur in the United States in 2022, including about 350 deaths per day from lung cancer.
Tucatinib Provides Lasting Survival Benefit in HER2+ Metastatic Breast Cancer
The 2-year overall survival rate was 51% in the tucatinib arm and 40% in the placebo arm.
NGS-Guided Therapy Did Not Improve Outcomes in Triple-Negative Breast Cancer
There were no significant differences in outcomes between patients who received physician’s choice of therapy and those who received genomically directed therapy.
- Loading...
Loading...
Next post in Breast Cancer
Loading... 
Loading...